Health Profound and Sustained Reductions in Lipoprotein(a) With Olpasiran Eli Pacheco Nov 23, 2022 0 Treatment with olpasiran -- a small interfering RNA product targeting lipoprotein(a), or Lp(a),…
Health Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for… Eli Pacheco Nov 9, 2022 0 Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone…